

Estetrol/Drospirenone to Reduce the Average Size of Endometriomas

NCT05837624

Status	RECRUITING
Phase	Phase 4
Sponsor	Andrew Zakhari
Enrollment	21 participants

Key Eligibility Criteria

Inclusion (3)

- Equal to or greater than 18 years old
- Has at least one ovarian endometrioma, of at least 3 cm
- Seeking a hormonal treatment for their endometrioma(s)

Exclusion (3)

- Any allergy or contraindication to the study drug
- Inability to provide informed consent
- Any hormone use, from the following list, within last 3 months (excluding hormones used for ovarian stimulation for fertility treatments): Estrogen (agonist or antagonist), Progestogen (agonist or antagonist), Androgen (agonist or antagonist), GnRH (agonist or antagonist), Cabergoline

Locations (1 total)

McGill University Health Center, Montreal, Quebec, Canada